Achondroplasia represents the most prevalent non-lethal chondrodysplasia in humans, presenting a distinct clinical phenotype characterized by disproportionate short stature, rhizomelic shortening of the limbs, macrocephaly, and characteristic craniofacial features. Arising from pathognomonic gain-of-function variants in the fibroblast growth factor receptor 3 gene (FGFR3), this monogenic skeletal dysplasia alters the precise temporal and spatial dynamics of endochondral ossification. Exploring achondroplasia requires an integrated perspective that bridges molecular genetics, cellular biology, multidisciplinary medical management, and evolving sociocultural paradigms surrounding disability.
Achondroplasia
1. Concise Definition
Achondroplasia is a dominant genetic disorder characterized by impaired endochondral ossification leading to disproportionate rhizomelic dwarfism, craniofacial disproportion, and characteristic musculoskeletal anomalies. It occurs predominantly as a consequence of a specific recurring missense mutation in the transmembrane domain of the FGFR3 gene on chromosome 4p16.3.
At the pathophysiological level, the condition manifests as constitutive activation of the FGFR3 tyrosine kinase receptor within epiphyseal growth plates. This aberrant signaling hyper-activates negative regulatory cascades that decelerate chondrocyte proliferation and inhibit terminal differentiation. Consequently, the longitudinal elongation of tubular bones is severely compromised, whereas periosteal and intramembranous ossification processes remain preserved, leading to normal trunk length paired with foreshortened extremities and disproportionate skull morphology.
Clinically, achondroplasia impacts multiple organ systems throughout the lifespan. Beyond physical stature, affected individuals face elevated risks for life-threatening cervicomedullary compression during infancy, central and obstructive sleep apnea, recurrent middle ear infections with secondary conductive hearing deficits, progressive lumbar spinal stenosis in adulthood, and marked biomechanical alterations that require proactive, anticipatory clinical surveillance.
2. Etymology & Linguistic Origin
The term achondroplasia derives from classical Greek roots: the prefix a- (ἀ-), meaning “without” or “absence of”; chondros (χόνδρος), signifying “cartilage” or “gristle”; and plasia, originating from plasis (πλάσις), meaning “formation,” “molding,” or “growth.” Translated literally, the term denotes “without cartilage formation” or “cartilage-deprived development.”
Historically, this etymological construction is scientifically inaccurate in a strict histopathological sense. Individuals with achondroplasia do not lack cartilage; rather, chondrocytes within the cartilaginous physis form normally but undergo defective, stunted proliferation, columnar organization, and hypertrophic differentiation. The term was formally introduced into clinical nomenclature in 1878 by the French physician and pathologist Jules Parrott to distinguish this intrinsic skeletal dysplasia from osteogenesis imperfecta, rickets, and other heterogeneous forms of micromelia.
3. Pronunciation & Grammatical Form
Achondroplasia is phonetically pronounced /eɪˌkɒn.droʊˈpleɪ.ʒə/ or /eɪˌkɑːn.drəˈpleɪ.zi.ə/. In medical linguistics, it serves as an uncountable abstract noun. The related adjectival form is achondroplastic (e.g., “achondroplastic dwarfism” or “achondroplastic chondrocyte”), while an individual diagnosed with the condition has historically been described clinically as an “achondroplastic individual” or more preferably within modern humanizing frameworks as a “person with achondroplasia.”
Orthographically, the term maintains uniform spelling across American and British English traditions, resisting variations seen in words containing diphthongs (such as pediatric vs. paediatric). Synonymous historical terminology found in nineteenth- and twentieth-century literature includes chondrodystrophia fetalis and chondrodystrophy, though these broader terms encompass heterogeneous conditions and have been replaced by the precise genetic diagnostic nomenclature specified in the nosology of genetic skeletal disorders.
4. Detailed Conceptual Explanation
To grasp the conceptual scope of achondroplasia, one must examine the divergent embryological and developmental processes governing human skeletogenesis. Human bones develop through two major distinct embryonic mechanisms: intramembranous ossification and endochondral ossification. Intramembranous ossification converts mesenchymal tissue directly into bone, forming flat bones such as the cranial vault, facial bones, and periosteal cortical surfaces. Conversely, endochondral ossification requires the formation of a temporary cartilaginous scaffold that is progressively degraded, vascularized, and replaced by mineralized osseous tissue. The latter process drives the longitudinal growth of all long tubular bones, axial vertebrae, and the skull base.
Achondroplasia is fundamentally a disorder of defective endochondral ossification. In the resting and proliferative zones of normal epiphyseal growth plates, resting chondrocytes undergo synchronized mitotic divisions, aligning themselves into neat, vertical longitudinal columns. These cells then transition through a pre-hypertrophic state into terminal hypertrophy, swelling markedly and secreting an extracellular matrix rich in type X collagen. Hypertrophic chondrocytes produce vascular endothelial growth factor (VEGF), attracting capillaries, osteoclasts, and osteoprogenitor cells that remodel the matrix into trabecular bone. In achondroplasia, the underlying molecular mutation keeps the FGFR3 receptor permanently turned on, which halts this orderly developmental cascade.
As a direct consequence, the growth plates in individuals with achondroplasia exhibit profound morphological disorganization. The columnar zone is extremely truncated, displaying erratic, hyper-vacuolated cells, premature cellular apoptosis, and stunted extracellular matrix synthesis. Because this physiological brake operates continuously across all physis plates, the long tubular bones—most prominently the proximal segments (femur and humerus)—fail to lengthen at physiological rates. This mechanism explains the clinical hallmark of rhizomelia, where the root or proximal components of limbs are disproportionately shorter than the intermediate (mesomelic) and distal (acromelic) components.
Concurrently, the differential impact of the mutation across distinct skeletal tissues creates the unique craniofacial phenotype. The human neurocranium expands via intramembranous ossification driven by brain volume enlargement; thus, the calvarium grows robustly, resulting in absolute or relative macrocephaly. In striking contrast, the cranial base (chondrocranium)—encompassing the sphenoid, ethmoid, and basilar occipital bones—develops strictly through endochondral ossification across the spheno-occipital and intersphenoid synchondroses. Premature fusion and stunted expansion of these synchondroses shorten the cranial base, causing midface hypoplasia, depressed nasal bridge, and narrowing of the foramen magnum.
5. Historical Development
Representations of disproportionate dwarfism consistent with achondroplasia date back to antiquity, making it one of the earliest documented medical conditions in human history. In ancient Egyptian iconography (circa 2500 BCE), deities such as Ptah and Bes were depicted with short-limbed dwarfism, and skeletal remains from tomb sites (such as the high-ranking official Seneb) demonstrate classic achondroplastic features, reflecting integration and religious veneration rather than marginalization.
During the Renaissance and early modern periods, individuals with achondroplasia were frequently retained as court dwarfs across European royal dynasties, as famously depicted in paintings by Diego Velázquez. However, formal scientific classification emerged only in the nineteenth century. In 1860, Rudolf Virchow examined neonatal cadavers displaying severe skeletal abnormalities, describing the pathology as “fetal rickets” under the erroneous belief that nutritional and inflammatory disturbances governed the observed osseous deformities.
The critical taxonomic breakthrough occurred in 1878, when Jules Parrott introduced the clinical entity achondroplasie. Parrott demonstrated through systematic postmortem autopsies that the primary lesion was non-inflammatory and confined strictly to the growth plates of cartilage, distinguishing it clearly from congenital syphilis and rickets. In 1900, Pierre Marie added precise semiotic descriptions, defining the characteristic “trident hand” (main en trident) configuration, the rhizomelic proportioning, and the spinal curvature patterns.
The twentieth century heralded the molecular genetic revolution. In 1994, an international research team led by John Wasmuth at the University of California, Irvine, identified the causative gene by mapping the locus to human chromosome 4p16.3 and identifying mutations in FGFR3. Simultaneously, work led by Françoise Le Merrer in France independently corroborated these findings, cementing achondroplasia as one of the most genetically homogeneous conditions ever characterized.
6. Theoretical Foundations
The molecular pathophysiology of achondroplasia rests on receptor tyrosine kinase (RTK) signal transduction pathways. FGFR3 belongs to a conserved family of transmembrane RTKs comprising an extracellular ligand-binding domain (containing three immunoglobulin-like loops, IgI–IgIII), a single hydrophobic transmembrane alpha-helix, and a split cytoplasmic intracellular tyrosine kinase domain. Under physiological conditions, binding of fibroblast growth factor ligands—particularly FGF9 and FGF18—induces receptor homodimerization, activating trans-autophosphorylation of tyrosine residues within the kinase loop.
In over 98% of achondroplasia cases, the pathology is driven by one of two specific nucleotide substitutions at genomic position 1138 of the FGFR3 coding region: c.1138G>A (accounting for approximately 98% of cases) or c.1138G>C (approximately 1-2%). Both single-nucleotide mutations translate into an identical amino acid substitution: the replacement of a neutral, hydrophobic glycine with a positively charged, hydrophilic arginine at codon 380 (p.Gly380Arg or G380R) in the transmembrane helix. This substitution introduces a charged residue that thermodynamically stabilizes the active dimeric conformation, dramatically elevating spontaneous ligand-independent cross-phosphorylation and delaying normal receptor endocytosis and lysosomal degradation.
Downstream intracellular cascades triggered by hyperactive FGFR3 signaling govern the phenotypic expression:
- The MAPK/ERK Cascade: Activated FGFR3 engages the FRS2 adapter protein, triggering the GRB2-SOS complex, which stimulates RAS, RAF, MEK1/2, and extracellular signal-regulated kinases 1 and 2 (ERK1/2). Sustained ERK1/2 phosphorylation inhibits chondrocyte matrix synthesis by downregulating SOX9 transcription factor activity, impairing type II collagen and aggrecan secretion.
- The STAT1 Pathway: FGFR3 directly phosphorylates signal transducer and activator of transcription 1 (STAT1). Translocated STAT1 dimers induce transcription of the cyclin-dependent kinase inhibitor p21 (CIP1/WAF1), which enforces early cell cycle arrest at the G1/S boundary, terminating chondrocyte proliferation prematurely.
- The PLCγ/PKC Pathway: Engagement of phospholipase C gamma stimulates protein kinase C, disrupting cytoskeletal actin remodeling and preventing coordinated cellular migration and column alignment within the growth plate.
Conversely, the natriuretic peptide pathway serves as a critical counter-regulatory mechanism. The binding of C-type natriuretic peptide (CNP) to its cognate membrane-bound guanylyl cyclase-B (GC-B/NPR-B) receptor generates intracellular cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), which selectively phosphorylates and inhibits RAF-1 kinase, thereby blocking the downstream FGFR3-driven MAPK/ERK cascade and restoring chondrocytic differentiation.
7. Key Components, Types & Dimensions
While classic achondroplasia exhibits a uniform genetic etiology, it exists within a continuum of FGFR3-related skeletal dysplasias and manifests distinct structural components across anatomical regions:
- Rhizomelic Skeletal Dysmorphology: Pronounced shortening of proximal long bones (femora and humeri) relative to forearm and lower leg bones, resulting in a low sitting-height-to-standing-height ratio and exaggerated upper-to-lower segment body proportions.
- Craniofacial Anomalies: Marked frontal bossing, hypoplasia of the midfacial structures and maxillary complex, relative mandibular prognathism, flattened nasal bridge, and narrow nasal passages.
- Craniocervical Junction Pathology: Significant structural constriction of the foramen magnum and early fusion of the posterior synchondroses, causing cervicomedullary compression and high risk of myelomalacia.
- Spinal Architecture Alterations: Thoracolumbar kyphosis during infancy (frequently evolving into pronounced lumbar hyperlordosis upon standing), progressive narrowing of interpedicular distances caudally along the lumbar spine, and premature symptomatic lumbar spinal canal stenosis.
- Appendicular Distal Aberrations: Trident hand presentation characterized by short, broad digits with persistent divergence between the third and fourth fingers, accompanied by limitation of complete elbow extension and forearm supination.
- Allelic Spectrum Variants: The broader spectrum of FGFR3 mutations includes Hypochondroplasia (a milder phenotype caused primarily by p.Asn540Lys), Thanatophoric Dysplasia Type I and II (severe, neonatally lethal conditions driven by constitutive activation), and SADDAN (Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans).
8. Examples & Illustrative Cases
To contextualize the longitudinal clinical trajectory of achondroplasia, consider two distinct patient scenarios illustrating early neurosurgical complications and late orthopedic challenges:
Case Illustration 1: Infant with Craniocervical Stenosis
An infant male is born at 39 weeks of gestation following a pregnancy marked by third-trimester ultrasound findings of shortened femurs and biparietal diameter exceeding the 97th percentile. Molecular diagnostics confirm a de novo c.1138G>A mutation in FGFR3. At four months of age, during routine follow-up, the clinical team observes marked central hypotonia, progressive head lag, asymmetric lower-extremity hyperreflexia, and sustained ankle clonus. Polysomnography reveals mixed central and obstructive apneas with an apnea-hypopnea index (AHI) of 14 events per hour.
High-resolution thin-cut computed tomography (CT) and magnetic resonance imaging (MRI) of the craniocervical junction demonstrate a severely narrowed, elliptical foramen magnum compressing the cervicomedullary junction, accompanied by localized intramedullary T2-hyperintensity indicative of early myelopathy. The patient undergoes urgent suboccipital decompression with cervical laminectomy of C1 and dura mater expansile plasty. Postoperatively, neurological examinations normalize, hypotonia resolves, and subsequent polysomnography demonstrates significant reduction in central apneas.
Case Illustration 2: Adult with Neurogenic Claudication
A 38-year-old woman with known achondroplasia presents with progressive lower extremity paresthesias, radiating bilateral sciatic pain, and walking tolerance reduced to less than 50 meters. She describes feelings of heavy, burning weakness across both calves that are alleviated only by resting with the lumbar spine flexed forward. Plain radiographs and magnetic resonance imaging demonstrate caudal tapering of the interpedicular distances from L1 to L5 combined with marked facet joint hypertrophy, short pedicles, and secondary disk bulges, causing multi-level central and lateral canal spinal stenosis.
Given the mechanical narrowing inherent to achondroplastic pedicle morphology, conservative interventions such as epidural injections provide only transient relief. The patient undergoes multi-segment wide decompressive lumbar laminectomy and medial facetectomy without destabilizing fusion. Following an intensive rehabilitation program, the neurogenic claudication fully abates, restoring baseline functional mobility.
9. Measurement & Assessment
The assessment and diagnosis of achondroplasia involve prenatal imaging, postnatal clinical evaluation, molecular genetic confirmatory testing, and longitudinal multidisciplinary anthropometric tracking.
Prenatal Screening & Diagnostics: Routine fetal ultrasonography typically detects achondroplasia late in the second or early in the third trimester (after 22–24 gestational weeks). The classic sonographic triad comprises: (1) marked lag in femoral and humeral length falling below the 5th percentile, (2) persistent macrocephaly with progressive frontal bossing, and (3) abnormal three-dimensional rendering of the trident hand configuration. Prenatal confirmation is performed via cell-free fetal DNA (cffDNA) extracted from maternal circulation or through diagnostic amniocentesis utilizing targeted Sanger sequencing or digital droplet PCR to detect the c.1138G>A/C variants.
Postnatal Clinical & Radiographic Criteria: Postnatal diagnosis is verified through targeted physical assessment and skeletal radiography. Pathognomonic radiographic signs include:
- Diminished caudal interpedicular distances throughout the lumbar vertebral spine (in contrast to the widening seen in unaffected individuals).
- Short, square-shaped iliac wings with flattened, horizontal acetabular roofs, giving the pelvis a characteristic “champagne glass” inner pelvic inlet shape.
- Deep sacrosciatic notches with distinctive proximal femoral radiolucency.
- Metaphyseal flare and irregularity with short, broad tubular bones displaying V-shaped metaphyseal indentations accommodating the epiphysis (chevron sign).
Longitudinal Monitoring: Growth monitoring cannot be performed using standard population growth curves, which would mischaracterize affected children as pathologically growth-restricted and microcephalic. Clinicians utilize specialized, disease-specific standardized growth reference charts (such as those established by Horton et al. and the American Academy of Pediatrics) to track length/height, weight-for-age, and head circumference percentiles. Neuroimaging (MRI of the posterior fossa and cervicomedullary junction) is mandatory during the first year of life, complemented by regular polysomnography and tympanometry.
10. Applications & Practical Significance
Management of achondroplasia has transitioned from reactive symptomatic treatment toward proactive, preventative, and targeted molecular therapies. The medical and social implications span multiple domains:
Pharmacological Therapeutics: The approval of vosoritide (an engineered recombinant C-type natriuretic peptide analog) by international regulatory agencies has transformed clinical care. Administered as a daily subcutaneous injection, vosoritide binds the NPR-B receptor to downregulate the hyperactive MAPK/ERK cascade, partially restoring endochondral ossification. Phase 3 clinical trials demonstrated an increase in annualized growth velocity of approximately 1.57 cm/year over placebo, accompanied by positive changes in upper-to-lower body proportionality. Additional investigational platforms include oral small-molecule tyrosine kinase inhibitors (e.g., infigratinib) and soluble decoy receptors (e.g., recifercept).
Neurosurgical and Orthopedic Interventions: Proactive neurosurgical screening mitigates the 2–5% risk of sudden infant death attributed to brainstem compression. Orthopedic interventions address thoracolumbar kyphosis through early postural hygiene (avoiding unsupported seating in infancy) and surgical bracing if deformities persist. Extensive surgical limb lengthening remains an elective option, utilizing external ring fixators or motorized intramedullary nails to gain 10–15 cm in height; however, it requires significant clinical commitment and carries notable risks of infection, nerve palsy, and joint contracture.
Otolaryngology & Dental Care: Midface hypoplasia precipitates persistent Eustachian tube dysfunction, causing serous otitis media and chronic conductive hearing loss. Early tympanostomy tube placement protects speech and language acquisition. Maxillary retrognathia and high-arched palatal morphology frequently induce severe Class III malocclusion, requiring orthodontic expansion and orthognathic surgical reconstruction.
11. Research & Empirical Evidence
Extensive population-based and translational investigations have elucidated the natural history, genetic architecture, and systemic outcomes of achondroplasia:
Epidemiology and Paternal Age Effect: The prevalence of achondroplasia is estimated at 1 in 15,000 to 1 in 28,000 live births globally. Over 80% of identified cases arise from spontaneous, de novo germline mutations in individuals with unaffected parents. Seminal epidemiological studies demonstrated an association between de novo mutations and advanced paternal age (typically >35 years). Research reveals a phenomenon known as “selfish spermatogonial selection”: the c.1138G>A mutation imparts a selective survival and clonal expansion advantage to mutated spermatogonial stem cells within the aging testis, explaining why this single point mutation exhibits one of the highest spontaneous mutation rates across the human genome.
Cardiovascular & Metabolic Morbidity: Cohort studies by Wynn et al. and modern multi-center registries indicate that adults with achondroplasia have higher rates of severe cardiovascular morbidity and increased mortality from early atherosclerotic heart disease compared to the general population. This risk is driven primarily by central obesity, secondary obstructive sleep apnea, and altered vascular hemodynamic compliance within foreshortened arterial beds.
Quality of Life Outcomes: The multicenter Lifetime Impact of Achondroplasia Study in Europe (LIAISE) and comparable North American natural history cohorts have evaluated health-related quality of life (HRQoL) using validated instruments like the SF-36 and PedsQL. Findings demonstrate significant physical functional limitations, high rates of chronic spinal and joint pain, and psychological challenges that intensify during adolescence and early adulthood, highlighting the need for comprehensive multidisciplinary care beyond height gains alone.
12. Cultural & Cross-Cultural Considerations
Cultural perceptions of achondroplasia vary significantly across historical eras and geopolitical landscapes. In Western societies, the media has long perpetuated tropes regarding individuals with disproportionate short stature, frequently relegating them to comedic spectacle, mythic novelty, or exploitative entertainment. In response, advocacy organizations, including Little People of America (LPA) founded by Billy Barty in 1957, and international counterparts like the Restricted Growth Association (RGA) in the UK, have worked to establish dwarfism as a recognized facet of physical disability and human diversity.
In cross-cultural contexts, sociological reception ranges widely. In low- and middle-income countries, significant structural barriers—such as architectural inaccessibility, limited specialized orthopedic services, and persistent superstitious stigmas—compound socioeconomic marginalization. Conversely, the rise of the global disability rights movement has fostered a cultural framework that views dwarfism through the social model of disability, arguing that the primary obstacles faced by individuals are built-environment barriers, institutional discrimination, and social bias rather than biological deficits.
13. Criticisms, Debates & Limitations
The management of achondroplasia has been complicated by major bioethical, clinical, and sociological controversies:
The Medicalization of Short Stature: The clinical introduction of vosoritide and emerging pharmaceutical agents has ignited fierce debate within the short-stature community. Critics, including disability scholars and certain factions of dwarf advocacy groups, argue that viewing short stature as an intrinsic medical defect to be corrected pharmacologically reinforces ableist paradigms. They contend that clinical resources are disproportionately directed toward height augmentation rather than dismantling societal barriers, promoting architectural accessibility, and addressing major medical complications such as spinal stenosis.
Bilateral Limb Lengthening Controversies: Extended limb lengthening procedures remain deeply controversial. While some patients and families seek these procedures to improve functional independence (such as reaching everyday objects, personal hygiene, and vehicle operation), the process involves years of painful surgical interventions, extended immobilization, and risks including osteomyelitis, nonunion, and long-term joint degeneration. The psychological impact of subjecting children or adolescents to prolonged orthopedic trauma remains an active debate among pediatric bioethicists.
Reproductive Decision-Making & Homozygous Lethality: When two individuals with heterozygous achondroplasia reproduce, each pregnancy carries a 25% risk of homozygous achondroplasia, an almost invariably lethal condition characterized by severe rib cage constriction, respiratory failure, and death in early infancy. The ethics surrounding pre-implantation genetic diagnosis (PGD), prenatal selective termination, and access to perinatal palliative care represent critical considerations in clinical genetic counseling.
14. Related Terms & Distinctions
Differential diagnosis requires distinguishing achondroplasia from other skeletal dysplasias within the FGFR3 family and broader chondrodystrophies:
- Hypochondroplasia: An allelic condition also caused by mutations in FGFR3 (predominantly p.Asn540Lys), presenting with milder disproportionate short stature, near-normal craniofacial features, and subtle radiographic findings that often delay diagnosis until mid-childhood.
- Thanatophoric Dysplasia: A severe, typically lethal skeletal dysplasia caused by different FGFR3 missense mutations (Types I and II) characterized by extreme micromelia, telephone-receiver-like curved femora, severe cloverleaf skull deformity, and thoracic hypoplasia causing neonatal pulmonary failure.
- Pseudoachondroplasia: An autosomal dominant skeletal dysplasia caused by mutations in the cartilage oligomeric matrix protein (COMP) gene. Unlike achondroplasia, individuals with pseudoachondroplasia have completely normal craniofacial features and head circumferences, but suffer from premature osteoarthrosis and joint laxity.
- Diastrophic Dysplasia: An autosomal recessive chondrodystrophy caused by mutations in the SLC26A2 sulfate transporter gene, distinct from achondroplasia due to the presence of cystic ear swelling (cauliflower ears), hitchhiker thumbs, severe clubfoot, and rigid spinal deformities.
- Growth Hormone Deficiency (Pituitary Dwarfism): An endocrine disorder characterized by proportionate short stature, normal skeletal ratios, preserved craniofacial proportions, and intact growth plates, contrasting with the rhizomelic disproportion of achondroplasia.
15. Summary / Key Takeaways
Achondroplasia is the archetypal human chondrodysplasia, caused by a recurring gain-of-function mutation (p.Gly380Arg) in the FGFR3 gene that constitutively suppresses endochondral ossification. This molecular lesion results in characteristic rhizomelic shortening of the limbs, macrocephaly, midface hypoplasia, and distinct spinal biomechanics. The condition demands proactive clinical surveillance throughout life to monitor for cervicomedullary compression, obstructive sleep apnea, and progressive lumbar spinal stenosis.
The therapeutic landscape has evolved from supportive orthopedic procedures toward targeted molecular interventions like vosoritide, which blocks aberrant intracellular signaling. Alongside clinical advances, active bioethical discourse emphasizes the need to harmonize medical therapies with the social model of disability, ensuring that care respects the agency and lived experiences of individuals with achondroplasia.
References
- Bober, M. B., Bellus, G. A., & Legare, J. M. (2020). Hypochondroplasia. In M. P. Adam, G. M. Mirzaa, & R. A. Pagon (Eds.), GeneReviews. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1477/
- Horton, W. A., Hall, J. G., & Hecht, J. T. (2007). Achondroplasia. The Lancet, 370(9582), 162–172. https://doi.org/10.1016/S0140-6736(07)61090-3
- Legeai-Mallet, L., & Savarirayan, R. (2020). Novel pharmacological therapies for achondroplasia: New hope for skeletal dysplasias. Bone, 141, 115579. https://doi.org/10.1016/j.bone.2020.115579
- Savarirayan, R., Tofts, L., Irving, M., Wilcox, W. R., Bacino, C. A., Hoover-Fong, J., & Day, R. (2020). Once-daily vosoritide in children with achondroplasia: Two-year results from a global phase 3 study. The Lancet, 396(10252), 684–692. https://doi.org/10.1016/S0140-6736(20)31541-5
- Shiang, R., Thompson, L. M., Zhu, Y. Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T., & Wasmuth, J. J. (1994). Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78(2), 335–342. https://doi.org/10.1016/0092-8674(94)90302-7